GLP-1s, Ohio, and the Cost of Waiting: What This Policy Shift Really Means for You

In ancient Norse tradition, they’d call this a thing, a gathering of minds leading us today to discuss.

On July 1, 2025, the State of Ohio will eliminate GLP-1 coverage for weight loss in state employee health plans. The official reason? A ballooning Medicaid bill—up from $172 million in 2021 to over $431 million in 2024 (Reuters). But let’s not confuse cause with cover story.

This isn’t about savings. It’s about slowing you down until the market catches up.

⏳ The Pause That Profits

Pharma didn’t fail. It succeeded too fast.

GLP-1s like Ozempic and Wegovy weren’t just popular—they were revolutionary. They disrupted treatment timelines, upended chronic disease management, and exposed how unprepared insurers, supply chains, and support industries really were. From gym culture to supplement stacks, no one was ready.

So the system does what it does best: delay access to consolidate control.

🧪 What’s Really in the Pipeline?

Ohio is pulling back, but Big Pharma is accelerating. Why? Because the next wave of GLP-1 treatments is already lining up:

• CagriSema – Semaglutide + amylin | ~23% weight loss | Phase III, 2027 (Barron’s)

• Amycretin – Oral GLP-1 + amylin | ~24% weight loss | In development (FT)

• Orforglipron – Oral GLP-1 from Eli Lilly | Late 2025 filing (Wired)

• Triple Agonists – Multi-hormone therapies for higher efficacy | Through 2026+ (Reuters)

These aren’t band-aids. They’re business models—designed to maintain pricing power, expand market reach, and extend patent life through 2032 and beyond.

🏛️ The Real Logic: Profit Protection, Not Cost Containment

Make no mistake—Ohio’s rollback isn’t a rejection of GLP-1s. It’s a safeguard. By pausing coverage, the state avoids premature market saturation while keeping chronic disease revenue streams intact.

• Fewer GLP-1 prescriptions = More diabetes care

• Slower weight loss = More bariatric surgeries

• More time = More monetization runway

That’s balance sheet logic. But for the individual trying to lose weight, improve mobility, or regain health—it’s betrayal.

❌ The Cost of Denial

Removing access to GLP-1s doesn’t just restrict treatment—it amplifies inequality:

• Those seeking better health lose access.

• Chronic disease treatments remain covered.

• The result? Incentivize illness, not prevention.

And whether intended or not, the message is clear:
Weight loss is a luxury, not a right—unless it’s profitable.

🛠️ So What Do You Do Now?

If you’ve lost GLP-1 access—or chose not to rely on it—you’re not out of options.
You’re just out of insurance support.

Here’s where to fight back:

• Lift weights to retain muscle mass (JAMA).

• Use protein tactically: Fairlife, IsoPure, Quest—tools that preserve lean mass (Obesity Reviews).

• Train with intent—not for calorie burn, but for metabolic control.

• Build community that isn’t built on a script pad.

🧭 Where MyoBio Stands

We don’t care how you got here—GLP-1, keto, stress, surgery, or all of the above.
We care how you hold the line while the industry plays catch-up.

MyoBio trains for sustainability—for muscle, for mood, for real metabolic health.

Because let’s be blunt:
They’re keeping you fat until it’s more profitable not to.

✅ Ready to Push Back?

• Book a My30 session to get your strength base locked in.

• Or schedule a full My90 assessment to rebuild the plan on your terms.

Wildfires, Water Pistols, and Buried Bars: The Danger of Misleading Fitness Articles

Ah, welcome. In ancient Norse tradition, they’d call this a thing, a gathering of minds and power, leading us today to confront an inconvenient truth fitness articles dangling low-hanging fruit so enticingly that it’s no longer on the branch, but lying on the ground, overripe and rotting. “One 20-Minute Workout Per Week Might Be All You Need!” it proclaims, a shiny bauble of convenience. At first glance, it seems like a gift. But as with all things too good to be true, there’s a catch.

This isn’t an indictment of simplicity,

simplicity has its place. This is about the dangerous allure of an accurate yet sorely misrepresented idea. Allow me to explain why this article well-meaning though it may be likely no longer serves you and why embracing it now would be nothing short of a disservice.

The articles, drawn from the Journal of Strength and Conditioning Research, boasts impressive first-year results: chest-press strength increased by 50%, leg-press strength by 70%. Extraordinary gains, on the surface. But dig deeper. This seven-year study reveals that those stellar numbers dwindle over time. Why? Because the human body is a brilliant adapter. It rises to meet the challenge, but without progression, it plateaus. At best, it stagnates. At worst, it begins a free fall.

This article’s promise is designed for the young and the uninitiated, for those taking their first tentative steps into fitness. For them, it’s a starting line—and a poor one at that. For you? It’s more likely a step back, a retreat, a white flag of surrender.

Here lies the larger problem. By the time we reach our 40s, our muscles are no longer passive assets. They’re battlegrounds. Sarcopenia, the gradual loss of muscle mass, is a relentless foe. It doesn’t ask permission; it simply takes. And one short session a week? That’s akin to fighting a wildfire with a squirt gun.

What’s required isn’t the least you can do it’s the most you can do efficiently. Two or three sessions a week. Compound lifts. Functional movements. Progressive overload. A diet rich in protein to fuel recovery. A regimen that blends strength, mobility, flexibility, and cardiovascular health.

Articles like this, with their low-hanging fruit, may be well-intentioned, but they do more harm than good. They whisper the sweet lies of mediocrity to those who should be reaching higher. They’re a permissive parent, swapping the broccoli of truth for the green gummy bears of convenience, simply because they’re the same color. They’re not a roadmap; they’re a cul-de-sac.

These types of articles, well-meaning as it may be, paint a ridiculous picture that has real consequences. It doesn’t lower the bar; it buries it in the sand and encourages others to bury their heads right alongside it, only to wonder later why their time feels wasted and their results are minimal. Thus, they slide backward even further.

This article doesn’t apply to you anymore. You’ve outgrown it. And that, my friends, is not just progress it’s triumph. It's time to Make Life More